Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood sugar marker could reveal hidden heart risks in Non-Diabetics

NCT ID NCT07154186

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at 180 non-diabetic adults with early coronary artery disease to see if a measure called the triglyceride-glucose index is linked to how many arteries are blocked. Participants will have a standard heart imaging test (angiogram) to map their artery disease. The goal is to find a simple way to identify higher-risk patients who might need closer monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict heart disease severity in non-diabetic patients using a simple blood test.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct changes in patient care, and results might not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This cross-sectional study will be conducted at Sohag University Hospitals, following approval from the institutional ethics committee.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old. * Both sexes. * Non-diabetic patients \[no history of diabetes, hemoglobin A1C (HbA1C) \< 6.5%, fasting glucose \< 126 mg/dL\]. * Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography. Exclusion Criteria: * Known diabetes mellitus (type 1 or type 2). * Previous history of coronary revascularization. * Severe hepatic or renal dysfunction \[alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)\< 30 mL/min/1.73 m²\]. * Malignant disease, autoimmune disease, or systemic inflammatory disorders. * Current use of triglyceride-lowering medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angiographic profiling are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angiographic profiling Coronary artery disease Non-diabetic Premature Triglycerides glucose index

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag University

    RECRUITING

    Sohag, 82511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.